NIB Holdings Ltd (ASX: NHF) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


NIB Holdings Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $3.28 billion
P/E Ratio 18.90
Dividend Yield 3.43%
Shares Outstanding 459.10 million
Earnings per share 0.385
Dividend per share 0.25
Year To Date Return 5.42%
Earnings Yield 5.29%
Franking 100%
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

NIB Holdings Ltd (ASX: NHF)
Latest News

Two businesspeople in suits run, one chasing the other.
Financial Shares

Why is the Medibank share price trailing NIB over the past year?

Could the NIB share price keep outperforming that of Medibank?

Read more »

A man leaps from a stack of gold coins to the next, each one higher than the last.
Dividend Investing

3 quality ASX dividend shares that have been sold off

These ASX dividend shares have seen their yields rise recently...

Read more »

private health insurance diagram.
Earnings Results

‘Real opportunity’: NIB (ASX:NHF) share price slips following first-half results

The NIB share price had a mixed trading session.

Read more »

share price plummeting down
Share Fallers

Why Ansell, AnteoTech, Dubber, and NIB shares are dropping

These ASX shares are in the red on Monday...

Read more »

Downward red arrow with business man sliding down it signifying falling asx share price.
Broker Notes

Why is the NIB (ASX:NHF) share price sliding 7% today?

JP Morgan is now bearish on NIB and reckons further downside is imminent.

Read more »

man holding two stacks of coins varying in size representing a comparison of dividend yields between Medibank and NIB
Healthcare Shares

How do Medibank (ASX:MPL) dividends compare to NIB?

How do the dividend yields of these 2 private healthcare insurers stack up for income investors?

Read more »

A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer
Growth Shares

Here are Scott Phillips’ top 5 ASX shares for 2022. Is it time to buy?

We peer into five ASX investment opportunities as mentioned by The Motley Fool's chief investment officer...

Read more »

A woman in yellow jump holds a coffee and writes in a diary.
Financial Shares

Own NIB (ASX:NHF) shares? Here are the key dates for your investor diary in 2022

What are the dates that investors should pencil in?

Read more »

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
03 Mar 2022 $0.1100 100.00% Interim 04 Apr 2022
02 Sep 2021 $0.1400 100.00% Final 05 Oct 2021
04 Mar 2021 $0.1000 100.00% Interim 06 Apr 2021
03 Sep 2020 $0.0400 100.00% Final 06 Oct 2020
05 Mar 2020 $0.1000 100.00% Interim 07 Apr 2020
02 Sep 2019 $0.1300 100.00% Final 30 Sep 2019
28 Feb 2019 $0.1000 100.00%
06 Sep 2018 $0.1100 100.00% Final 05 Oct 2018
01 Mar 2018 $0.0900 100.00% Interim 03 Apr 2018
07 Sep 2017 $0.1050 100.00% Final 06 Oct 2017
02 Mar 2017 $0.0850 100.00% Interim 03 Apr 2017
08 Sep 2016 $0.0900 100.00% Final 07 Oct 2016
02 Mar 2016 $0.0575 100.00% Interim 01 Apr 2016
09 Sep 2015 $0.0600 100.00% 09 Oct 2015
04 Mar 2015 $0.0550 100.00% 02 Apr 2015
10 Sep 2014 $0.0900 100.00% Special Cash 03 Oct 2014
10 Sep 2014 $0.0575 100.00% Final 03 Oct 2014
05 Sep 2013 $0.0500 100.00% Final 04 Oct 2013
04 Mar 2013 $0.0500 100.00% Interim 05 Apr 2013
05 Mar 2012 $0.0425 100.00% Interim 05 Apr 2012
07 Mar 2011 $0.0400 100.00% Interim 08 Apr 2011
05 Mar 2010 $0.0200 100.00% Interim 08 Apr 2010
14 Sep 2009 $0.0440 100.00% Final 09 Oct 2009

NHF ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About NIB Holdings Ltd

NIB Holdings Limited (ASX:NHF) was originally known as Newcastle Industrial Benefits. The company was established in the Hunter region of New South Wales in 1952 to provide health insurance for workers at the BHP steelworks. Since its humble beginnings, NIB has grown to become a national and international insurer with a notable share of the Australian and New Zealand private health insurance market.

Beyond health insurance, NIB also provides life insurance as well as travel insurance to its customers across Australia and around the world. NIB is now Australia’s third largest provider of travel insurance.

According to the company’s website, NIB provides health insurance to over 1.6 million people across Australia and New Zealand as well as nearly 200,000 international students and overseas workers in Australia.

The health fund was demutualised on 19 July 2007 and, on the same day, became Australia’s first private health fund to list on the ASX. The NIB share price opened its first day of trade at 85 cents and has since gone on to reach as high as $8 in July 2019.

NHF Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 May 2022 $7.15 $-0.13 -1.79% 597,118 $7.28 $7.28 $7.09
13 May 2022 $7.28 $0.15 2.10% 1,513,928 $7.15 $7.28 $7.07
12 May 2022 $7.13 $-0.11 -1.52% 1,067,574 $7.25 $7.25 $7.08
11 May 2022 $7.24 $0.04 0.56% 1,438,657 $7.10 $7.24 $7.06
10 May 2022 $7.20 $0.07 0.98% 1,286,742 $7.12 $7.20 $7.08
09 May 2022 $7.13 $-0.07 -0.97% 946,441 $7.17 $7.24 $7.10
06 May 2022 $7.20 $-0.03 -0.41% 1,254,052 $7.22 $7.29 $7.13
05 May 2022 $7.23 $0.11 1.54% 783,280 $7.09 $7.25 $7.04
04 May 2022 $7.12 $0.10 1.42% 1,013,947 $7.12 $7.12 $7.02
03 May 2022 $7.02 $-0.05 -0.71% 1,133,406 $7.06 $7.18 $7.00
02 May 2022 $7.07 $-0.01 -0.14% 940,331 $7.03 $7.12 $7.02
29 Apr 2022 $7.08 $0.07 1.00% 611,332 $7.01 $7.08 $6.98
28 Apr 2022 $7.01 $0.02 0.29% 672,809 $7.03 $7.10 $6.99
27 Apr 2022 $6.99 $0.22 3.25% 2,048,338 $6.78 $7.02 $6.73
26 Apr 2022 $6.77 $-0.09 -1.31% 458,435 $6.84 $6.85 $6.77
22 Apr 2022 $6.86 $0.03 0.44% 925,332 $6.81 $6.90 $6.77
21 Apr 2022 $6.83 $0.17 2.55% 1,528,500 $6.76 $6.86 $6.71
20 Apr 2022 $6.66 $0.03 0.45% 856,658 $6.63 $6.74 $6.62

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
07 Mar 2022 Mark Fitzgibbon Transfer 40 $250,400
Off-market transfer.
28 Feb 2022 Anne Loveridge Buy 11 $74,137
On-market trade.
26 Nov 2021 Mark Fitzgibbon Issued 220 $1,515,326
Issue of securities. 951,637 - Performance Rights
11 Nov 2021 Mark Fitzgibbon Sell 47 $340,264
On-market trade.
22 Sep 2021 Mark Fitzgibbon Transfer 10 $67,255
Off-market transfer. Estimated Value
14 Sep 2021 Mark Fitzgibbon Sell 30 $199,599
On-market trade.
14 Sep 2021 Mark Fitzgibbon Transfer 4 $31,064
Off-market transfer. Estimated Value
09 Sep 2021 Mark Fitzgibbon Sell 30 $200,845
On-market trade.
09 Sep 2021 Mark Fitzgibbon Transfer 10 $66,111
Off-market transfer. Estimated Value
08 Sep 2021 Mark Fitzgibbon Sell 25 $168,301
On-market trade.
08 Sep 2021 Mark Fitzgibbon Transfer 20 $134,428
Off-market transfer. Estimated Value
01 Sep 2021 Mark Fitzgibbon Buy 142 $968,658
Conversion of securities.
01 Sep 2021 Mark Fitzgibbon Issued 82 $559,194
Issue of securities.
01 Sep 2021 Mark Fitzgibbon Expiry 79 $538,521
As advised by the company. 731,386 - Performance Rights
01 Sep 2021 Mark Fitzgibbon Exercise 142 $968,658
Conversion of securities. 810,814 - Performance Rights
30 Aug 2021 Mark Fitzgibbon Sell 30 $201,000
On-market trade.
30 Aug 2021 Peter Harmer Buy 11 $74,998
On-market trade.
31 May 2021 Steven (Steve) Crane Sell 47 $293,027
On-market trade.
27 May 2021 Steven (Steve) Crane Sell 102 $633,200
On-market trade.
26 May 2021 David Gordon Buy 30 $184,795
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr David L Gordon Non-Executive DirectorNon-Executive Chairman May 2020
Mr Gordon has over 20 years' experience as a director of both public and private companies and has experience in the corporate advisory and financial services sector. He is currently Chair of Accent Group Limited and Founding Principal of Lexicon Partners. He was previously a Director and Chair of Ten Network Holdings and held senior roles at Herbert Smith Freehills and boutique investment bank, Wentworth Associates.
Ms Anne Joan Loveridge Non-Executive Director Feb 2017
Ms Loveridge has over 35 years of experience in banking, wealth management, private equity and property. She has knowledge of financial and regulatory reporting, risk management controls and compliance frameworks. She also has experience as a Committee Chairperson. Formally trained as a Chartered Accountant, Anne has a of experience in financial reporting, auditing, risk, ethics and regulatory affairs following her 31 years with PwC Australia, where she retired as Partner and Deputy Chair in 2015. Through senior leadership roles in the firm, Anne also has experience and a focus on leadership, performance and culture. She was specifically involved in the creation of targets, mentoring and development programs for senior executives, as well as evaluating organisational training programs to identify areas of bias. Anne Loveridge is entitled to receive a retirement benefit from PwC as part of her retirement plan. The amount of the payment was determined at the time of retirement, based on role and tenure with the firm. The benefit is not impacted by the revenue, profits or earnings of PwC. Anne has declared her previous relationship with PwC to the nib Board and the Board is satisfied that it does not affect her independence as Non-Executive Director and does not constitute a conflict of interest. The nib Board has in place mechanisms to manage conflicts of interest where they arise. Anne is a Non-Executive Director of Platinum Asset Management and a Non-Executive Director of National Australia Bank Limited. She is a member of the Risk, Reputation and Investment committee.
Mr Donal Paul O'Dwyer Non-Executive Director Mar 2016
Mr O'Dwyer is also a Director of nib health funds limited. Industry experience Donal has a knowledge of the health industry globally, after more than 35 years in senior executive and Non-Executive Director roles within the healthcare products and medical device sectors. He went on to gain experience in business, science, engineering, manufacturing and management. During his tenure with Baxter Healthcare, he rose through the ranks from plant manager to President of the Cardiovascular Group Europe, gaining a understanding of the inner workings of business strategy and fiscal management, from the floor of the factory through to the boardroom. He then worked for Cordis (the cardiovascular device franchise of Johnson & Johnson) - initially as European President and later, when he located to the US, he served as Worldwide President. In his role as member of the nib Risk and Reputation Committee, Donal has a interest in environmental, social and governance factors and how these performance indicators can help promote long-term financial success. Donal is a Non-Executive Director of Cochlear Ltd, Mesoblast Ltd (Chair of the Nomination and Remuneration Committee) and Fisher & Paykel Healthcare Corporation Ltd. He was director of Chair of CardieX Limited (formerly AtCor Medical Holdings Limited). He is Chair of the Investment committee and a member of the Risk and Reputation and People committee.
Mark Fitzgibbon Chief Executive OfficerManaging Director May 2007
Mr Fitzgibbon has held executive positions at a number of large Australian organisations, including local government councils and peak bodies. Mark has previously served as CEO of both the national and NSW peak industry bodies for licensed clubs, as well as holding several General Manager positions in local government. He is currently a Director of Private Healthcare Australia.
Ms Lee Ausburn Non-Executive Director Nov 2013
Ms Ausburn has more than 30 years of experience in the pharmaceuticals industry. Lee is a pharmacist with experience in retail and hospital pharmacy, as well as in academia. She had a long career in the pharmaceutical industry with Merck Sharp and Dohme (Australia) Pty Ltd and was previously Vice President - Asia for Merck and Co Inc with responsibility for the company's operations across nine countries. She also has marketing experience with customer centric. Operating in a highly regulated industry, Lee also developed regulatory and government relations skills. She also has experience operating joint ventures, including chairing the Far East Operating Board. Lee was previously a member (2010-2015) and President (2015- 2017) of the Pharmacy Foundation at the University of Sydney. In NSW, she was a Board member of NSW Health's Clinical Excellence Commission and the Agency for Clinical Innovation (2010-2014), established to enhance quality and safety in NSW hospitals. Lee is currently a Director of pharmaceutical wholesaling and pharmacy retail business, Australian Pharmaceutical Industries Ltd. She is Chair of the People committee and a member of the Risk and Reputation committee.
Mr Peter Harmer Non-Executive Director Jul 2021
Mr Harmer has over 40 years' experience in the Australian and international insurance and financial sectors, including over 30 years in a senior executive capacity. He was formerly Chief Executive Officer of Insurance Australia Group (IAG), CGU Insurance, Aon Limited UK, Aon Risk Services Australia Pacific and Aon Re Australia. Mr Harmer was also Chairman of Aon Re Australia and the London Market Reform Group and is currently a Non-Executive Director of the Commonwealth Bank of Australia.
Ms Jacqueline Chow Non-Executive Director Apr 2018
Ms Chow has more than 20 years of experience working with global blue-chip consumer product multinationals in a range of executive and non-executive positions in general management, strategy, marketing as well as technology and innovation. Her early career concentrated on business analytics, brand equity and marketing. She has global experience driving strategic growth and innovation across customer and consumer brands for the likes of Fonterra, Campbell Arnott's and the Kellogg Company. She was previously Deputy Chair of Global Dairy Platform and a Director of Fisher & Paykel Appliances in New Zealand, Dairy Partners Americas, the Riddet Institute (Massey University NZ) and The Arnott's Foundation. In her role with McKinsey & Company RTS, she advises clients across resources, retail, financial services, telecommunications and consumer sectors on organisational change and high performance culture. She is Non-Executive Director of the Australia-Israel Chamber of Commerce and a senior advisor with McKinsey & Company RTS. She is also a member of Chief Executive Women. She is Chair of the Risk and Reputation committee and a member of the People and Investment committee.
Mrs Michelle McPherson Deputy Chief Executive OfficerChief Financial Officer Sep 2008
Ms Roslyn Toms Group Executive - Legal and Chief Risk OfficerCompany Secretary Apr 2013
Mr Jordan French Senior Corporate CounselJoint Company Secretary Aug 2017
Edward Close Chief Executive Australian Residents Health Insurance
James Barr Chief Executive International Visitors
Anna Gladman Chief Executive nib Travel
Nick Freeman Chief Financial Officer
Brendan Mills Chief Information Officer
Matt Paterson Chief Operations Officer
Martin Adlington Chief People Officer
Michelle McPherson Deputy Chief Executive OfficerChief Financial Officer
Roslyn Toms Group Executive - Legal and Chief Risk OfficerCompany Secretary
Jordan French Senior Corporate CounselJoint Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 76,781,000 16.77%
Citicorp Nominees Pty Limited 33,999,128 7.43%
J P Morgan Nominees Australia Pty Limited 33,045,560 7.22%
National Nominees Limited 15,798,859 3.45%
BNP Paribas Noms Pty Ltd 7,731,251 1.69%
Bnp Paribas Nominees Pty Ltd 5,440,256 1.19%
Citicorp Nominees Pty Limited (i) 4,381,265 0.96%
Mirrabooka Investments Limited 1,350,000 0.29%
Mr Mark Anthony Fitzgibbon 1,296,366 0.28%
BNP Paribas Nominees Pty Ltd Six Sis Ltd 1,239,620 0.27%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd 1,050,124 0.23%
HSBC Custody Nominees (Australia) Limited (i) 1,013,776 0.22%
CPU Share Plans Pty Ltd 960,641 0.21%
BNP Paribas Nominees Pty Ltd (i) 913,923 0.20%
Powerwrap Limited 889,889 0.19%
Fitzy (Nsw) Pty Ltd 824,621 0.18%
BNP Paribas Noms Pty Ltd (i) 769,996 0.17%
AMP Life Limited 732,813 0.16%
Mrs Michelle Mcpherson 587,911 0.13%
Modane Pty Ltd 459,744 0.10%